A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants
Purpose
The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.
Condition
- Healthy Volunteers
Eligibility
- Eligible Ages
- Between 18 Years and 65 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Laboratory values meet the criteria specified in the protocol. - A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
Exclusion Criteria
- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment. - Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study treatment administration. - Use of tobacco- or nicotine-containing products within 3 months (90 days) prior to the first dose of study treatment. - Participant has prior exposure to ABBV-722 within 90 days prior to the first dose of study treatment.
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Basic Science
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Period 1 & 2 |
In Period 1, participants will receive a single dose of ABBV-722. In Period 2, participants will receive multiple daily doses of Itraconazole and a single dose of ABBV-722. |
|
Recruiting Locations
Acpru /Id# 282143
Grayslake, Illinois 60030
Grayslake, Illinois 60030
More Details
- Status
- Recruiting
- Sponsor
- AbbVie